The Promising Role of the Potential Medical Benefits of Cannabidiol Derived from an Herbal Plant to Enhance the Hepatic Defense in Adult Male Rats

Abstract

A critical natural chemical substance present in cannabis Sativa plants that may have therapeutic benefits is Cannabidiol or CBD. The inquiry was made to assess CBD's possible protection against liver injury. Fifty Sprague-Dawley male rats weighing (150±25g) were divided into five equal groups. Group I received distilled water orally, while Group II received an intraperitoneal injection of Doxorubicin (18 mg/kg bwt). Group III received CBD orally, while Group IV received 1 ml of CBD (26 mg/kg bwt) and Group V received Trimetazidine (10 mg/kg bwt), in addition to a single dose of Doxorubicin (18 mg/kg bwt) on the 11th day for both groups (IV, V). The results revealed that the administration of CBD (26 mg/kg bwt) demonstrated a significant improvement in lowering liver enzyme activity (ALT and AST), as well as an impact on decreasing tumor necrosis factor-alpha (TNF- α), interleukin 6 (IL-6), and MDA in liver tissue linked to liver histopathology results, resulting in an increase in serum levels of albumin, total protein, and oxidative stress parameters (SOD and GSH) in rats. In conclusion, Cannabidiol's potential protective properties may be due to its anti-inflammatory and antioxidant properties. Thus, CBD-derived compounds have long saved interest as a cure for a broad choice of hepatic disorders .